Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: Nov. 1, 2022

Colorectal cancer (CRC) is the third most common and second leading cause of cancer-related death worldwide. Countless CRC patients undergo disease progression. As a hallmark cancer, Warburg effect promotes metastasis remodels tumor microenvironment, including promoting angiogenesis, immune suppression, cancer-associated fibroblasts formation drug resistance. Targeting metabolism would be promising method for treatment CRC. In this review, we summarize information about roles in microenvironment to elucidate mechanisms governing identify novel targets therapy.

Language: Английский

---

Fluorescent dyes based on rhodamine derivatives for bioimaging and therapeutics: recent progress, challenges, and prospects

Chemical Society Reviews, Journal Year: 2023, Volume and Issue: 52(16), P. 5607 - 5651

Published: Jan. 1, 2023

Since their inception, rhodamine dyes have been extensively applied in biotechnology as fluorescent markers or for the detection of biomolecules owing to good optical physical properties. Accordingly, they emerged a powerful tool visualization living systems. In addition fluorescence bioimaging, molecular design derivatives with disease therapeutic functions (e.g., cancer and bacterial infection) has recently attracted increased research attention, which is significantly important construction libraries diagnostic integration. However, reviews focusing on integrated strategies dye-based diagnosis treatment wide application are extremely rare. this review, first, brief history development dyes, transformation from bioimaging therapy, concept optics-based integration its significance human presented. Next, systematic review several excellent rhodamine-based well treatment, Finally, challenges practical future outlook clinical translation also discussed.

Language: Английский

---

Cancer Therapeutic Targeting of Hypoxia Induced Carbonic Anhydrase IX: From Bench to Bedside

Cancers, Journal Year: 2022, Volume and Issue: 14(14), P. 3297 - 3297

Published: July 6, 2022

Carbonic Anhydrase IX (CAIX) is a major metabolic effector of tumor hypoxia and regulates intra- extracellular pH acidosis. Significant advances have been made recently in the development therapeutic targeting CAIX. These approaches include antibody-based immunotherapy, as well use antibodies to deliver toxic radioactive payloads. In addition, large number small molecule inhibitors which inhibit enzymatic activity CAIX described. this commentary, we highlight current status strategies both pre-clinical clinical space, discuss future perspectives that leverage inhibition combination with additional targeted therapies enable effective, durable for cancer therapy.

Language: Английский

---

The role of lipid metabolic reprogramming in tumor microenvironment

Theranostics, Journal Year: 2023, Volume and Issue: 13(6), P. 1774 - 1808

Published: Jan. 1, 2023

Metabolic reprogramming is one of the most important hallmarks malignant tumors.Specifically, lipid metabolic has marked impacts on cancer progression and therapeutic response by remodeling tumor microenvironment (TME).In past few decades, immunotherapy revolutionized treatment landscape for advanced cancers.Lipid plays pivotal role in regulating immune to immunotherapy.Here, we systematically reviewed characteristics, mechanism, cells TME, appraised effects various cell death modes (specifically ferroptosis) metabolism, summarized antitumor therapies targeting metabolism.Overall, profound microenvironment; therefore, may lead development innovative clinical applications including sensitizing immunotherapy.

Language: Английский

---

FOXM1: A small fox that makes more tracks for cancer progression and metastasis

Seminars in Cancer Biology, Journal Year: 2023, Volume and Issue: 92, P. 1 - 15

Published: March 22, 2023

Language: Английский

---

“Three birds with one stone” nanoplatform: Efficient near‐infrared‐triggered type‑I AIE photosensitizer for mitochondria‐targeted photodynamic therapy against hypoxic tumors

Aggregate, Journal Year: 2024, Volume and Issue: unknown

Published: March 24, 2024

Abstract Currently three major problems seriously limit the practical application of cancer photodynamic therapy (PDT): (i) hypoxic tumor microenvironment (TME); (ii) low generation efficiency toxic reactive oxygen species (ROS) in aggregates and (iii) shallow tissue penetration depth excitation light. Very limited approaches are available for addressing all above with a single design. Herein, rational “three birds one stone” molecular nanoengineering strategy is demonstrated: nanoplatform U‐Ir@PAA‐ABS based on covalent combination lanthanide‐doped upconversion nanoparticles (UCNPs) an AIE‐active dinuclear Ir(III) complex provides concentration‐dependent type‐I photochemical process upon 980 nm irradiation by Föster resonance energy transfer (FRET). targets mitochondria has excellent phototoxicity even severe hypoxia environments irradiation, inducing dual‐mode cell death mechanism apoptosis ferroptosis. Taken together, vitro vivo results demonstrate successful improving efficacy PDT against tumors.

Language: Английский

---

Vanillic acid restores homeostasis of intestinal epithelium in colitis through inhibiting CA9/STIM1-mediated ferroptosis

Pharmacological Research, Journal Year: 2024, Volume and Issue: 202, P. 107128 - 107128

Published: March 2, 2024

The damage of integrated epithelial epithelium is a key pathogenic factor and closely associated with the recurrence ulcerative colitis (UC). Here, we reported that vanillic acid (VA) exerted potent therapeutic effects on DSS-induced by restoring intestinal homeostasis via inhibition ferroptosis. By CETSA assay DARTS assay, identified carbonic anhydrase IX (CAIX, CA9) as direct target VA. binding VA to CA9 causes insulin-induced gene-2 (INSIG2) interact stromal interaction molecule 1 (STIM1), rather than SREBP cleavage-activating protein (SCAP), leading translocation SCAP-SREBP1 from endoplasmic reticulum (ER) Golgi apparatus for cleavage into mature SREBP1. activation SREBP1 induced then significantly facilitated transcription SCD1 exert an inhibitory effect inhibiting excessive death cells caused ferroptosis, effectively preserved integrity barrier prevented progression unresolved inflammation. In conclusion, our study demonstrated could alleviate through CA9/STIM1-mediated providing promising candidate UC.

Language: Английский

---

Targeting triple negative breast cancer stem cells using nanocarriers

Discover Nano, Journal Year: 2024, Volume and Issue: 19(1)

Published: March 7, 2024

Abstract Breast cancer is a complex and heterogeneous disease, encompassing various subtypes characterized by distinct molecular features, clinical behaviors, treatment responses. Categorization of based on the presence or absence estrogen receptor (ER), progesterone (PR), human epidermal growth factor 2 (HER2), leading to such as luminal A, B, HER2-positive, triple-negative breast (TNBC). TNBC, comprising around 20% all cancers, lacks expression ER, PR, HER2 receptors, rendering it unresponsive targeted therapies presenting significant challenges in treatment. TNBC associated with aggressive behavior, high rates recurrence, resistance chemotherapy. Tumor initiation, progression, are attributed stem cells (BCSCs), which possess self-renewal, differentiation, tumorigenic potential. Surface markers, self-renewal pathways (Notch, Wnt, Hedgehog signaling), apoptotic protein (Bcl-2), angiogenesis inhibition (VEGF inhibitors), immune modulation (cytokines, checkpoint inhibitors) among key targets discussed this review. However, targeting BCSC subpopulation presents challenges, including off-target effects, low solubility, bioavailability anti-BCSC agents. Nanoparticle-based offer promising approach target cellular processes implicated survival BSCS TNBC. In review, we explore nanocarrier-based approaches for BCSCs aiming overcome these improve outcomes patients. These nanoparticle-based therapeutic strategies hold promise addressing gap delivering while minimizing systemic toxicity enhancing efficacy. Graphical abstract

Language: Английский

---

Radiopharmaceuticals and their applications in medicine

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: Jan. 2, 2025

Abstract Radiopharmaceuticals involve the local delivery of radionuclides to targeted lesions for diagnosis and treatment multiple diseases. Radiopharmaceutical therapy, which directly causes systematic irreparable damage cells, has attracted increasing attention in refractory diseases that are not sensitive current therapies. As Food Drug Administration (FDA) approvals [ 177 Lu]Lu-DOTA-TATE, Lu]Lu-PSMA-617 their complementary diagnostic agents, namely, 68 Ga]Ga-DOTA-TATE Ga]Ga-PSMA-11, radiopharmaceutical-based theranostics (radiotheranostics) being increasingly implemented clinical practice oncology, lead a new era radiopharmaceuticals. The generation radiopharmaceuticals utilizes targeting vector achieve accurate avoid off-target deposition, making it possible improve efficiency biosafety tumour therapy. Numerous studies have focused on developing novel broader range disease targets, demonstrating remarkable vivo performance. These include high tumor uptake, prolonged retention time, favorable pharmacokinetic properties align with standards. While radiotheranostics been widely applied applications now expanding neurodegenerative diseases, cardiovascular inflammation. Furthermore, radiotheranostic-empowered precision medicine is revolutionizing cancer paradigm. Diagnostic play pivotal role patient stratification planning, leading improved therapeutic outcomes radionuclide This review offers comprehensive overview evolution radiopharmaceuticals, including both FDA-approved clinically investigated explores mechanisms cell death induced by It emphasizes significance future prospects theranostic-based advancing medicine.

Language: Английский

---

Insights into tumor-derived exosome inhibition in cancer therapy

European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: 285, P. 117278 - 117278

Published: Jan. 13, 2025

Language: Английский

---